Parallax Volatility Advisers
SRPT icon

Parallax Volatility Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Parallax Volatility Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,000
Closed -$319K – 1797
2025
Q1 		$319K Hold
5,000
– – ﹤0.01% 1268
2024
Q4 		$608K Hold
5,000
– – ﹤0.01% 1464
2024
Q3 		$624K Hold
5,000
– – ﹤0.01% 1472
2024
Q2 		$790K Sell
5,000
-25,000
-83% -$3.21M ﹤0.01% 1323
2024
Q1 		$3.88M Buy
30,000
+24,000
+400% +$2.94M 0.01% 811
2023
Q4 		$579K Hold
6,000
– – ﹤0.01% 1564
2023
Q3 		$727K Hold
6,000
– – ﹤0.01% 1492
2023
Q2 		$687K Sell
6,000
-1,500
-20% -$193K ﹤0.01% 1545
2023
Q1 		$1.03M Sell
7,500
-74,300
-91% -$9.64M ﹤0.01% 1488
2022
Q4 		$10.6M Buy
81,800
+63,300
+342% +$7.34M 0.02% 749
2022
Q3 		$2.04M Hold
18,500
– – ﹤0.01% 1424
2022
Q2 		$1.39M Hold
18,500
– – ﹤0.01% 1512
2022
Q1 		$1.45M Sell
18,500
-41,500
-69% -$3.18M ﹤0.01% 1501
2021
Q4 		$5.4M Buy
60,000
+10,000
+20% +$855K 0.01% 767
2021
Q3 		$4.62M Hold
50,000
– – ﹤0.01% 857
2021
Q2 		$3.89M Buy
50,000
+25,000
+100% +$1.9M 0.01% 733
2021
Q1 		$1.86M Buy
25,000
+21,200
+558% +$1.96M ﹤0.01% 712
2020
Q4 		$646K Sell
3,800
-107,900
-97% -$16M ﹤0.01% 1582
2020
Q3 		$15.7M Buy
111,700
+85,400
+325% +$13M 0.01% 808
2020
Q2 		$4.21M Buy
26,300
+14,000
+114% +$1.91M ﹤0.01% 1143
2020
Q1 		$1.2M Buy
+12,300
New +$1.41M ﹤0.01% 1421
2019
Q2 		– Sell
-7,000
Closed -$834K – 3670
2019
Q1 		$834K Buy
+7,000
New +$900K ﹤0.01% 1345
2017
Q1 		– Sell
-400,000
Closed -$11M – 4587
2016
Q4 		$11M Buy
400,000
+64,800
+19% +$2.6M 0.02% 412
2016
Q3 		$20.6M Buy
+335,200
New +$10.1M 0.04% 273
2016
Q1 		– Sell
-15,000
Closed -$579K – 3607
2015
Q4 		$579K Hold
15,000
– – ﹤0.01% 1479
2015
Q3 		$482K Hold
15,000
– – ﹤0.01% 1549
2015
Q2 		$456K Buy
+15,000
New +$307K ﹤0.01% 1667

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's SRPT Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 85 shares — an estimated $1.83K sold.

Parallax Volatility Advisers first reported a position in SRPT in Q3 2016 and held it in 20 quarters. The position peaked at $4.45M in Q4 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 85 Sarepta Therapeutics shares in Q1 2026, an estimated $1.83K.
  • Parallax Volatility Advisers first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 20 quarters.
  • Parallax Volatility Advisers's Sarepta Therapeutics position peaked at $4.45M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.